Stocks
Fate Therapeutics (FATE) EBITDA US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | -211.1 | -294.6 | -172.2 | -176.6 | -127.0 | -121.6 | ||
| Changes by years, y/y, % | +69% | +40% | -42% | +3% | -28% | +0.3% | |||
Fate Therapeutics. EBITDA US GAAP, bln rub
Fate Therapeutics. EBITDA US GAAP, changes, %
Fate Therapeutics. EBITDA US GAAP, sum by quarters, bln rub
Fate Therapeutics (FATE) EBITDA US GAAP (quarter values) |
||||||||
| FY2025Q1 | FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2026Q1 | LTM ? | |||
| EBITDA, bln rub | ? | -37.9 | -30.8 | -29.0 | -29.3 | -28.3 | -121.6 | |
| Changes by years, y/y, % | -18% | -24% | -39% | -31% | -25% | |||
| Changes by quarters, q/q, % | -10% | -19% | -6% | +1% | -3% | |||
